Pulse Biosciences (NASDAQ:PLSE – Get Free Report) released its earnings results on Wednesday. The company reported ($0.21) earnings per share (EPS) for the quarter, RTT News reports. During the same period in the prior year, the business posted ($0.19) earnings per share.
Pulse Biosciences Trading Down 8.5 %
Shares of PLSE stock traded down $1.51 during trading hours on Thursday, hitting $16.21. The company’s stock had a trading volume of 28,685 shares, compared to its average volume of 199,472. The business has a fifty day moving average of $17.70 and a 200-day moving average of $14.22. Pulse Biosciences has a twelve month low of $4.24 and a twelve month high of $22.69. The stock has a market cap of $993.51 million, a price-to-earnings ratio of -20.01 and a beta of 1.74.
Wall Street Analyst Weigh In
Separately, StockNews.com raised Pulse Biosciences to a “sell” rating in a report on Friday, September 20th.
Pulse Biosciences Company Profile
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Read More
- Five stocks we like better than Pulse Biosciences
- How to Invest in Blue Chip Stocks
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- What Do S&P 500 Stocks Tell Investors About the Market?
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
